Milk thistle is the top-selling liver supplement. The best trials show no benefit.

Milk thistle, whose active extract is silymarin, is the most widely sold supplement marketed for liver health — and the best evidence for it is a null result. A Cochrane systematic review found no significant effect on the outcomes that matter, and a rigorously designed, NIH-funded randomised trial found that even higher-than-usual doses did not improve a standard marker of liver injury [s1] [s2].

What the trials found

The most complete synthesis is a Cochrane review that pooled 18 randomised clinical trials in 1,088 patients with alcohol-related and/or hepatitis B or C liver disease [s1]. Its verdict was constrained by weak underlying studies — only 28.6% of the trials met high methodological-quality criteria — but the pooled results were unambiguous [s1]. Compared with placebo or no treatment, milk thistle had no significant effect on mortality (relative risk 0.78, 95% confidence interval 0.53 to 1.15), on complications of liver disease (RR 0.95, 0.83 to 1.09), or on liver histology [s1]. A reduction in liver-related mortality appeared when all trials were pooled (RR 0.50, 0.29 to 0.88), but that signal disappeared once the analysis was restricted to the high-quality trials (RR 0.57, 0.28 to 1.19) — the pattern you expect when an apparent benefit is an artefact of weak studies rather than a real effect [s1]. The authors concluded that the results question milk thistle's benefit and highlight the lack of high-quality supporting evidence [s1].

A later, better-designed trial did not rescue it. In a multicentre, double-blind, placebo-controlled trial published in JAMA, 154 people with chronic hepatitis C and elevated liver enzymes, who had already failed interferon therapy, were randomly assigned to 420 mg of silymarin, 700 mg of silymarin, or placebo three times a day for 24 weeks [s2]. The primary outcome — getting liver enzyme (ALT) levels into the normal range or down by at least half — was met by exactly two participants in each group (3.8% on placebo, 4.0% on 420 mg, 3.8% on 700 mg; P ≥ .99) [s2]. The mean decline in ALT did not differ across the three groups (P = .75), and neither did hepatitis C viral levels or quality-of-life measures [s2]. The authors concluded that higher-than-customary doses of silymarin did not reduce liver enzymes more than placebo [s2].

What the agencies say, and a quality problem

The NIH's National Center for Complementary and Integrative Health summarises the state of evidence as insufficient to draw definite conclusions about milk thistle's effects on health conditions, and notes that two trials it funded — one in hepatitis C, one in the fatty-liver condition steatohepatitis — did not show benefit from silymarin supplementation [s3]. Its summary of the broader liver literature is that results across alcohol-related liver disease, hepatitis B and C, non-alcoholic fatty liver disease and chemotherapy- or toxin-related liver problems have been conflicting or too limited to support conclusions [s3].

Where a faint signal does exist, it is not about the liver at all. The NCCIH notes that a small number of studies suggest milk thistle extracts may help control blood sugar in people with type 2 diabetes — but most of that research was done in Middle Eastern countries, and whether the results would hold elsewhere is unclear [s3]. That is a candidate finding in a different condition, not evidence for the liver-protection claim the supplement is mainly sold on.

Milk thistle's reputation is old: its extract, silymarin, is a mixture of compounds, and the plant was used historically for liver disorders long before controlled trials existed, which is part of why it remains a top-selling liver supplement today [s3]. Longevity of use, however, is not the same as evidence of effect — and the controlled trials that have since been run are the reason the popularity and the evidence now point in different directions.

There is also a product-integrity issue that is easy to miss. The NCCIH flags concerns about the poor chemical and microbiological quality of milk thistle supplements sold in the US and elsewhere: some products have been found to contain amounts of silymarin substantially different from what the label states, or to be contaminated with pesticides, microorganisms, or mycotoxins [s3]. On tolerability, milk thistle taken by mouth appears well tolerated, with the most common side effects being digestive — bloating, nausea and gas — though it can cause allergic reactions in people sensitive to related plants such as ragweed, and can interact with medicines [s3].

What this leaves a reader with

For improving liver disease, the strongest available evidence — a Cochrane review and a well-conducted randomised trial — does not support milk thistle, and what a bottle actually contains is not guaranteed to match its label [s1] [s2] [s3]. Anyone weighing a supplement alongside prescription medicines has a specific reason to raise it with a clinician first, because herb-drug interactions are real [s3].

This article is informational and is not medical advice.

Sources

• Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases — Cochrane Database of Systematic Reviews, 2007-10-17
• Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial — JAMA, 2012-07-01
• Milk Thistle: Usefulness and Safety — National Center for Complementary and Integrative Health (NIH)